Literature DB >> 11850282

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.

Carmen Betriu1, Iciar Rodríguez-Avial, Blas Ali Sánchez, María Gómez, Juan Alvarez, Juan J Picazo.   

Abstract

The antimicrobial activities of tigecycline (GAR-936) were compared with those of other agents against 1,087 strains recently isolated in 12 Spanish medical centers. Tigecycline showed activity against a wide spectrum of aerobic and anaerobic bacteria, including strains such as methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, penicillin-resistant Streptococcus pneumoniae, Enterococcus faecium, Acinetobacter baumannii, and Stenotrophomonas maltophilia.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11850282      PMCID： PMC127504          DOI： 10.1128/AAC.46.3.892-895.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.

Authors:  A C Labbé; A M Bourgault; J Vincelette; P L Turgeon; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.

Authors:  D B Hoellman; G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).

Authors:  R N Jones; M A Pfaller
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

4.  Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.

Authors:  P L Ho; T L Que; D N Tsang; T K Ng; K H Chow; W H Seto
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

Authors:  C Edlund; C E Nord
Journal:  Clin Microbiol Infect       Date:  2000-03       Impact factor: 8.067

7.  In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

Authors:  R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal:  Diagn Microbiol Infect Dis       Date:  2000-11       Impact factor: 2.803

8.  Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species.

Authors:  V Peset; P Tallón; C Sola; E Sánchez; A Sarrión; C Pérez-Bellés; A Vindel; E Cantón; M Gobernado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-10       Impact factor: 3.267

9.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors:  D K Chen; A McGeer; J C de Azavedo; D E Low
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

10.  Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.

Authors:  T M Murphy; J M Deitz; P J Petersen; S M Mikels; W J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191
View more
  25 in total

1.  In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  M D Kitzis; A Ly; F W Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  [New antimicrobial drugs: an update].

Authors:  Heinz Burgmann
Journal:  Wien Med Wochenschr       Date:  2003

3.  In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.

Authors:  Emilia Cercenado; Sonia Cercenado; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

4.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

5.  Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.

Authors:  Karen Lolans; Thomas W Rice; L Silvia Munoz-Price; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

Authors:  F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

7.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 8.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

9.  Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.

Authors:  Radosław Izdebski; Ewa Sadowy; Janusz Fiett; Paweł Grzesiowski; Marek Gniadkowski; Waleria Hryniewicz
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

Review 10.  Targeting cancer cell mitochondria as a therapeutic approach.

Authors:  Shijun Wen; Daqian Zhu; Peng Huang
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.